David Gandara, M.D.

David R. Gandara, M.D.

Specialties

Hematology/Oncology

Internal Medicine

Department

Internal Medicine

Title

  • Professor - Emeritus
  • Director, Thoracic Oncology Program
  • Senior Advisor to Director, UC Davis Comprehensive Cancer Center

Reviews

David R. Gandara is not currently accepting new patients. For assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

Additional Phone Numbers

Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Research/Academic Interests

Dr. Gandara's research interests focus on developmental therapeutics of new anti-cancer agents as well as preclinical modeling and clinical research in lung cancer. He is the principal investigator on an Early Therapeutics award from the National Cancer Institute (NCI), where he leads an interdisciplinary team of clinical oncologists, pharmacologists, molecular biologists and statisticians in developing new anti-cancer agents in a variety of novel drug classes. He also leads a multi-specialty team in the Southwest Oncology Group (SWOG), an NCI-funded national clinical research organization, in studies related to improving therapies for lung cancer and developing predictive biomarkers of therapeutic efficacy. 

Dr. Gandara is also the UC Davis principal investigator for a multi-institutional collaboration (iGXT: integrated Genetically-engineered mouse models, patient-derived Xenografts, and Clinical Trials) between the NCI Center for Advanced Preclinical Research (CAPR) and Jackson Laboratory, an NCI-designated basic cancer center. The goal of this iGXT project is to develop better preclinical models to optimize cancer drug development and speed the transition to personalized cancer therapy.

Division

Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.D., University of Texas Medical Branch at Galveston, Galveston TX 1973

B.A., University of Texas, Austin TX 1969

Internship: Internal Medicine, Madigan Army Medical Center, Tacoma WA 1973-1976

Residency

Internal Medicine, Madigan Army Medical Center, Tacoma WA 1973-1976

Fellowships

Hematology/Oncology, Letterman Army Medical Center, Presidio of San Francisco CA 1976-1978

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Medical Oncology,

California Board of Quality Medical Assurance,

Texas State Board of Medical Examiners,

Professional Memberships

Alpha Omega Alpha

American Medical Association

American Society for Cancer Research

American Society of Hematology

Fellow, American College of Physicians

Multinational Association for Supportive Care in Cancer

Secretary-Treasurer and member of the Board of Directors of the American Society of Clinical Oncology (ASCO)

Secretary-Treasurer and member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC)

Honors and Awards

Newsweek Health: Top Cancer Doctors, 2015

Castle Connolly America's Top Doctors for Cancer (2006-2016), 2016

Castle Connolly America's Top Doctors (2001-2016), 2016

Addario Lung Cancer Foundation Collaborative Research Award, 2014

Murren Lectureship Award, Yale Comprehensive Cancer Center, 2014

International Association for the Study of Lung Cancer (IASLC) Scientific Award., 2013

Bonnie J. Addario Lung Cancer Foundation Lectureship Award, 2010

Who's Who Among Executives and Professionals, Honors Edition, 2008, 2009

Statesman Award, American Society of Clinical Oncology, 2008

The Dr. Fred Marcus �Simply The Best� Award, Bonnie J. Addario Lung Cancer Foundation, 2008

Director�s Service Award, National Cancer Institute, 2008

UCD Dean's Mentorship Award, 2003

Longmire Lectureship, Scripps Cancer Center, 2002

Top Cancer Specialists for Women: Lung Cancer, Good Housekeeping Magazine, 1999

Oettinger Memorial Award: Lung Cancer Research, 1998

Semlar Visiting Professorship, Boston University, 1993

Outstanding Attending Physician, Martinez VA Medical Center, 1987

Outstanding Resident Teacher, Madigan Army Medical Center, 1974

Secretary-Treasurer (Freshman & Sophomore Classes), University of Texas Medical Branch, Galveston TX, 1969, 1970

Research Preceptorship in Physiology, 1969

Alpha Epsilon Delta, National Premedical Honor Society, 1969

Phi Theta Kappa, National Honor Society, 1969

Who's Who in American Colleges, 1967

National Rotary Award: Scholarship and Leadership, 1967

Select Recent Publications

For a comprehensive list of Dr. Gandara's publications, please click here (opens new window).

Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mass LA, Arrieta O, Richardet E, Vallejos C, Wistuba I, Gandara D, Hirsch F. Challenges in facing the lung cancer epidemic and treating advanced disease in Latin America. Clin Lung Cancer. 2017 Jan;18(1):e71-79. doi:10.1016/j.cllc.2016.05.003. Epub 2016 Jun 5.

Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer. 2017 Jan;18(1):5-12. Published online 2016 Jun 27. doi:10.1016/j.cllc.2016.06.007.

Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line. Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):43-49.  doi:10.1016/j.cllc.2016.05.011. Epub 2016 Jun 4.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive non-small cell lung cancer: status in 2016. J Thorac Oncol. 2016 Jul;11(7):946-63. doi:10.1016/j.jtho.2016.05.008. Epub 2016 May 23.

Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 Jun;34(3): 355-63. doi:10.1007/s10637-016-0335-x. Epub 2016 Mar 21.

Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 May;11(5): 613-38. doi:10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22.

Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar;17(2):113-118.e2. Published online 2015 Oct 23. doi:10.1016/j.cllc.2015.09.003.

Gandara, DR, Redman, M, Hirsch, FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2016 Mar;2(3):300-1. doi:10.1001/jamaoncol.2015.4920.

Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr;11(4):453-74. doi:10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30.

Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar;11(3):420-5. PMID:26725184  PMCID:PMC4775366  doi:10.1016/j.jtho.2015.11.003.